Cision Newshttps://news.cision.comCision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.Thu, 09 Jul 2026 12:46:02 GMTCision News14660https://news.cision.comhttps://news.cision.com/Content/img/news-logo.pngHerantis Pharma will present at the BioStock Life Science Summit, November 20https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-will-present-at-the-biostock-life-science-summit--november-20,c4059611cision4931091Mon, 04 Nov 2024 10:00:00 GMTHerantis Pharma Plc’s shares subscribed with option rightshttps://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-plc-s-shares-subscribed-with-option-rights,c3807053cision4590761Wed, 19 Jul 2023 05:00:00 GMTHerantis Pharma Plc announcing start of recruitment of healthy volunteers for part 2 of the ongoing Phase 1a clinical study of HER-096https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-plc-announcing-start-of-recruitment-of-healthy-volunteers-for-part-2-of-the-ongoing-,c3799638cision4581730Tue, 04 Jul 2023 09:05:00 GMTHerantis Pharma Oyj: Managers' Transactions – Aki Prihtihttps://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-oyj--managers--transactions---aki-prihti,c3790382cision4569634Tue, 20 Jun 2023 07:30:00 GMTHerantis Pharma Oyj: Managers' Transactions – Henri Huttunenhttps://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-oyj--managers--transactions---henri-huttunen,c3790394cision4569642Tue, 20 Jun 2023 07:30:00 GMTHerantis Pharma Oyj: Managers' Transactions – Timo Veromaahttps://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-oyj--managers--transactions---timo-veromaa,c3790387cision4569659Tue, 20 Jun 2023 07:30:00 GMTHerantis Pharma Oyj: Managers' Transactions – Frans Wuitehttps://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-oyj--managers--transactions---frans-wuite,c3790405cision4569661Tue, 20 Jun 2023 07:30:00 GMTHerantis Pharma Oyj: Managers' Transactions – Tone Kvålehttps://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-oyj--managers--transactions---tone-kvale,c3784090cision4561481Fri, 09 Jun 2023 11:17:00 GMTHerantis Pharma Oyj: Managers' Transactions – Antti Vuolantohttps://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-oyj--managers--transactions---antti-vuolanto,c3784094cision4561473Fri, 09 Jun 2023 11:15:00 GMTHerantis Pharma Oyj: Managers' Transactions – Henri Huttunenhttps://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-oyj--managers--transactions---henri-huttunen,c3784063cision4561477Fri, 09 Jun 2023 11:15:00 GMTHerantis Pharma Plc's board decides on new option rights program for managing director, management team and other key personnelhttps://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-plc-s-board-decides-on-new-option-rights-program-for-managing-director--management-t,c3779544cision4554601Fri, 02 Jun 2023 12:00:00 GMTHerantis Pharma to participate in Redeye Hosted Events: Investor Lunch and Redeye Growth Dayhttps://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-to-participate-in-redeye-hosted-events--investor-lunch-and-redeye-growth-day,c3773060cision4545627Tue, 23 May 2023 07:00:00 GMTHerantis Pharma to participate in Bio€quity Europe 2023 in Dublin May 2023https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-to-participate-in-bio-quity-europe-2023-in-dublin-may-2023,c3761557cision4529986Tue, 02 May 2023 08:45:00 GMTDecisions of Herantis Pharma Plc’s Annual General Meeting of shareholdershttps://news.cision.com/herantis-pharma-oyj/r/decisions-of-herantis-pharma-plc-s-annual-general-meeting-of-shareholders,c3754884cision4520143Thu, 20 Apr 2023 10:35:00 GMTHerantis Pharma announces first healthy volunteer dosed in the Phase 1a clinical study for the Parkinson’s disease drug candidate, HER-096https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-announces-first-healthy-volunteer-dosed-in-the-phase-1a-clinical-study-for-the-parki,c3753894cision4518958Wed, 19 Apr 2023 08:00:00 GMTHerantis Pharma has signed European Innovation Council (EIC) Accelerator grant agreementhttps://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-has-signed-european-innovation-council--eic--accelerator-grant-agreement,c3749280cision4512607Wed, 12 Apr 2023 05:00:00 GMTHerantis Pharma to participate in Nordic Health Summit Japan 2023https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-to-participate-in-nordic-health-summit-japan-2023,c3748043cision4511013Thu, 06 Apr 2023 06:00:00 GMTNotice to Convene Herantis Pharma Plc's Annual General Meeting of Shareholdershttps://news.cision.com/herantis-pharma-oyj/r/notice-to-convene-herantis-pharma-plc-s-annual-general-meeting-of-shareholders,c3742176cision4502358Tue, 28 Mar 2023 10:46:16 GMTHerantis Pharma published the Annual report for 2022https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-published-the-annual-report-for-2022,c3741784cision4501746Tue, 28 Mar 2023 05:00:00 GMTHerantis Pharma to participate in Bio-Europe Spring and AD/PD 2023https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-to-participate-in-bio-europe-spring-and-ad-pd-2023,c3730042cision4485787Thu, 09 Mar 2023 07:00:00 GMTCORRECTION: Herantis publishes 2H & FY 2022 Reporthttps://news.cision.com/herantis-pharma-oyj/r/correction--herantis-publishes-2h---fy-2022-report,c3772869cision4485204Wed, 08 Mar 2023 11:57:00 GMTHerantis publishes 2H & FY 2022 Reporthttps://news.cision.com/herantis-pharma-oyj/r/herantis-publishes-2h---fy-2022-report,c3726444cision4480319Thu, 02 Mar 2023 06:00:00 GMTHerantis Pharma: Invitation to 2H & FY 2022 report webinar on March 2, 2023https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma--invitation-to-2h---fy-2022-report-webinar-on-march-2--2023,c3719979cision4471474Tue, 21 Feb 2023 11:00:00 GMTHerantis Pharma announces approval of Clinical Trial Application (CTA) for a Phase 1 study for HER-096https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-announces-approval-of-clinical-trial-application--cta--for-a-phase-1-study-for-her-0,c3718950cision4470593Mon, 20 Feb 2023 11:00:00 GMT